

Appl. No. : Unknown
Filed : Herewith

56. A method of treating cardiac hypertrophy in a patient wherein the cardiac hypertrophy has been induced by a cardiac disease other than hypertrophic cardiomyopathy of viral origin, characterized by the presence of an elevated level of $\text{PGF}_{2\alpha}$ comprising administering to the patient a therapeutically effective amount of interferon gamma ($\text{IFN-}\gamma$).

57. The method of claim 56 wherein the cardiac disease is myocardial infarction.

58. A method of treating cardiac hypertrophy in a patient wherein the cardiac hypertrophy has been induced by myocardial infarction and is characterized by the presence of an elevated level of $\text{PGF}_{2\alpha}$ comprising administering to the patient a therapeutically effective amount of interferon gamma ($\text{IFN-}\gamma$).

59. The method of claim 58 wherein said $\text{IFN-}\gamma$ is initiated within 48 hours following myocardial infarction.--

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: November 16, 2000

By: Ginger R. Dreger
Ginger R. Dreger
Registration No. 33,055
Attorney of Record
620 Newport Center Drive
Sixteenth Floor
Newport Beach, CA 92660
(415) 954-4114